Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78‐week prospective study
Authors:
- Gui‐Qiang WangGWGui‐Qiang Wang
- Hong ZhaoHZHong Zhao
- China HepB‐Related Fibrosis Assessment Research GroupCGChina HepB‐Related Fibrosis Assessment Research Group
- 5 October 2018
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (4) , 755-763
Abstract
Background and Aim: Little reliable data are available about the liver stiffness measurement (LSM) for fibrosis monitoring in chronic hepatitis B (CHB) patients on antiviral therapy. We aimed to assess the accuracy of LSM in fibrosis monitoring during 78‐week antiviral therapy in CHB patients.Methods: Five hundred fifty‐six treatment‐naïve CHB patients with qualified LSM and liver biopsy at baseline were analyzed. Patients receiving entecavir‐based therapy were prospectively followed to 78 weeks for second LSM and liver biopsy. Serologic detection, LSM, and liver biopsy were performed on the same day. Necro‐inflammatory activity was also evaluated.Results: Areas under receiver operating characteristics curves of LSM at baseline and week 78 for significant fibrosis (≥ F3), advanced fibrosis (≥ F4), and liver cirrhosis (≥ F5) was 0.84, 0.87, 0.83 and 0.76, 0.85, 0.88, respectively. Patients with the same fibrosis stage but higher histology activity index score tend to have higher LSM at baseline. Liver stiffness decreased rapidly (3.8 [1.6–8.6] kPa) in parallel with baseline histology activity index scores from 11.3 (7.8–16.7) kPa at baseline to 6.4 (5.1–8.8) kPa at week 78. Greater decline of LSM in patients with only inflammation improvement was observed as compared with those without inflammation improvement (5.2 [2.5–9.7] vs 1.8 [0.2–8.1] kPa, P = 0.013). Baseline Ishak fibrosis score was the only predictor of 78‐week fibrosis improvement (odds ratio, 1.859; P = 0.000).Conclusions: In CHB patients receiving 78‐week antiviral treatment, LSM could diagnosis different liver fibrosis stages, decrease in absolute LSM value could reflect the remission of liver inflammation, and baseline Ishak fibrosis score was the only predictor for 78‐week fibrosis reversion.Keywords
Funding Information
- Project of Beijing Science and Technology Committee (D121100003912002)
- China Mega-Project for Innovative Drugs (2016ZX09101065)
- China Mega-Project for Infectious Diseases (2017ZX10203202, 2013ZX10002005, 2012ZX10002006, 2013ZX10002004, 2012ZX10005005)
This publication has 26 references indexed in Scilit:
- On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B PatientsAntiviral Therapy, 2011
- Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3‐year follow‐up studyJournal of Viral Hepatitis, 2011
- Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)Journal of Hepatology, 2010
- Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis CGut, 2008
- Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver diseaseGut, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis CHepatology, 2004
- Human Hepatic Stellate Cells Show Features of Antigen–Presenting Cells and Stimulate Lymphocyte ProliferationHepatology, 2003
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995